methane has been researched along with Cholera Infantum in 30 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
| Excerpt | Relevance | Reference |
|---|---|---|
| " It was reported that colonic methane production is far more frequent in cystic fibrosis (CF) patients than in other subjects." | 7.75 | Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection. ( Lisowska, A; Walkowiak, J; Wójtowicz, J, 2009) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "The measurement of hydrogen-methane breath gases is widely used in gastroenterology to evaluate malabsorption syndromes and bacterial overgrowth." | 4.02 | Hydrogen-methane breath testing results influenced by oral hygiene. ( Erdrich, S; Harnett, JE; Hawrelak, JA; Myers, SP; Tan, ECK, 2021) |
| " It was reported that colonic methane production is far more frequent in cystic fibrosis (CF) patients than in other subjects." | 3.75 | Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection. ( Lisowska, A; Walkowiak, J; Wójtowicz, J, 2009) |
| " Since there are two gases (hydrogen and methane) measured on lactulose breath testing, we evaluated whether the different gas patterns on lactulose breath testing coincide with diarrhea and constipation symptoms in IBS and IBD." | 3.72 | Methane production during lactulose breath test is associated with gastrointestinal disease presentation. ( Chow, EJ; Hasan, A; Kong, Y; Mayer, AG; Park, S; Pimentel, M, 2003) |
| "Hydrogen plays a key role in many microbial metabolic pathways in the human gastrointestinal tract (GIT) that have an impact on human nutrition, health and wellbeing." | 2.61 | Hydrogen cross-feeders of the human gastrointestinal tract. ( Altermann, EH; McNabb, WC; Roy, NC; Shorten, PR; Smith, NW, 2019) |
| "The functional gastrointestinal disorders (FGIDs) have a high prevalence and are associated with high healthcare costs." | 1.62 | [Functional Exams in the gastroenterology - new developments and tips for the common practice]. ( Barbone, G; Jochum, C, 2021) |
| "Functional gastrointestinal disorders (FGID) are defined by broad phenotypic descriptions and exclusion of recognizable disease." | 1.48 | Fermentable Sugar Ingestion, Gas Production, and Gastrointestinal and Central Nervous System Symptoms in Patients With Functional Disorders. ( Drewes, AM; Materna, A; Olesen, SS; Wilder-Smith, CH, 2018) |
| "We assess the deep vein thrombosis (DVT) and small intestinal bacterial overgrowth (SIBO) in SCI." | 1.46 | Association between small-intestinal bacterial overgrowth and deep vein thrombosis in patients with spinal cord injuries. ( Cheng, X; Lian, YJ; Xie, NC; Xu, HL; Zhang, L, 2017) |
| "One hundred sixteen patients with gastrointestinal diseases were studied." | 1.27 | Factors affecting methane production in humans. Gastrointestinal diseases and alterations of colonic flora. ( Gilat, T; Hallak, A; Peled, Y; Weinberg, D, 1987) |
| "Patients with Crohn's disease, ulcerative colitis, and pneumatosis cystoides intestinalis had significantly lower prevalences of methane excretion (13%, 15%, and 11% respectively)." | 1.27 | Methane excretion in man--a study of breath, flatus, and faeces. ( Brydon, WG; Eastwood, MA; McKay, LF, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 12 (40.00) | 24.3611 |
| 2020's | 7 (23.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, H | 1 |
| Li, HZ | 1 |
| Wang, YR | 1 |
| Song, Y | 1 |
| Wang, BM | 1 |
| Cao, HL | 1 |
| Jiang, K | 1 |
| Santos, ANDR | 1 |
| Soares, ACF | 1 |
| Oliveira, RP | 1 |
| Morais, MB | 1 |
| Kim, YJ | 1 |
| Paik, CN | 1 |
| Lee, JM | 1 |
| Kim, DB | 1 |
| Yang, JM | 1 |
| Erdrich, S | 1 |
| Tan, ECK | 1 |
| Hawrelak, JA | 1 |
| Myers, SP | 1 |
| Harnett, JE | 1 |
| Barbone, G | 1 |
| Jochum, C | 1 |
| Rezaie, A | 4 |
| Buresi, M | 2 |
| Lembo, A | 1 |
| Lin, H | 1 |
| McCallum, R | 1 |
| Rao, S | 2 |
| Schmulson, M | 1 |
| Valdovinos, M | 1 |
| Zakko, S | 1 |
| Pimentel, M | 2 |
| Paterson, W | 1 |
| Camilleri, M | 1 |
| Simren, M | 1 |
| Boeckxstaens, G | 1 |
| Vanner, SJ | 1 |
| Tuck, CJ | 1 |
| Yao, CK | 1 |
| Philpott, HL | 1 |
| Barrett, JS | 1 |
| Maltz, C | 1 |
| Usai-Satta, P | 2 |
| Giannetti, C | 1 |
| Oppia, F | 1 |
| Cabras, F | 1 |
| Rao, SS | 1 |
| Wilder-Smith, CH | 1 |
| Olesen, SS | 1 |
| Materna, A | 1 |
| Drewes, AM | 1 |
| Smith, NW | 1 |
| Shorten, PR | 1 |
| Altermann, EH | 1 |
| Roy, NC | 1 |
| McNabb, WC | 1 |
| D'Angelo, G | 1 |
| Di Rienzo, TA | 1 |
| Scaldaferri, F | 1 |
| Del Zompo, F | 1 |
| Pizzoferrato, M | 1 |
| Lopetuso, LR | 1 |
| Laterza, L | 1 |
| Bruno, G | 1 |
| Petito, V | 1 |
| Campanale, MC | 1 |
| Cesario, V | 1 |
| Franceschi, F | 1 |
| Cammarota, G | 1 |
| Gaetani, E | 1 |
| Gasbarrini, A | 2 |
| Ojetti, V | 1 |
| Cheng, X | 1 |
| Zhang, L | 1 |
| Xie, NC | 1 |
| Xu, HL | 1 |
| Lian, YJ | 1 |
| Corazza, GR | 1 |
| Gasbarrini, G | 1 |
| Montalto, M | 1 |
| Di Stefano, M | 1 |
| Basilisco, G | 1 |
| Parodi, A | 1 |
| Satta, PU | 1 |
| Vernia, P | 1 |
| Anania, C | 1 |
| Astegiano, M | 1 |
| Barbara, G | 1 |
| Benini, L | 1 |
| Bonazzi, P | 1 |
| Capurso, G | 1 |
| Certo, M | 1 |
| Colecchia, A | 1 |
| Cuoco, L | 1 |
| Di Sario, A | 1 |
| Festi, D | 1 |
| Lauritano, C | 1 |
| Miceli, E | 1 |
| Nardone, G | 1 |
| Perri, F | 1 |
| Portincasa, P | 1 |
| Risicato, R | 1 |
| Sorge, M | 1 |
| Tursi, A | 1 |
| Lisowska, A | 1 |
| Wójtowicz, J | 1 |
| Walkowiak, J | 1 |
| Mayer, AG | 1 |
| Park, S | 1 |
| Chow, EJ | 1 |
| Hasan, A | 1 |
| Kong, Y | 1 |
| Majewski, M | 1 |
| Reddymasu, SC | 1 |
| Sostarich, S | 1 |
| Foran, P | 1 |
| McCallum, RW | 1 |
| Liu, Y | 1 |
| Whitman, WB | 1 |
| Peled, Y | 1 |
| Weinberg, D | 1 |
| Hallak, A | 1 |
| Gilat, T | 1 |
| Hoshi, T | 1 |
| Kitame, F | 1 |
| Homma, M | 1 |
| Ishikawa, M | 1 |
| McKay, LF | 1 |
| Eastwood, MA | 1 |
| Brydon, WG | 1 |
| Newman, A | 1 |
| Weingärtner, L | 1 |
| Sitka, U | 1 |
| Patsch, R | 1 |
| Gründig, C | 1 |
| Valla, A | 1 |
| Verwaerde, JC | 1 |
| Yue, NN | 1 |
| Xu, HM | 1 |
| Xu, J | 1 |
| Zhu, MZ | 1 |
| Zhang, Y | 1 |
| Tian, CM | 1 |
| Nie, YQ | 1 |
| Yao, J | 1 |
| Liang, YJ | 1 |
| Li, DF | 1 |
| Wang, LS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Is the Vegetarian Version of Therapeutic Carbohydrate Restriction as Effective as the Omnivore Version: In the Context of Remission of Type 2 Diabetes[NCT05579561] | 19 participants (Actual) | Interventional | 2022-05-11 | Active, not recruiting | |||
| Evaluation of GIMate Handheld Hydrogen Breath Monitor for Diagnosis of Lactose Malabsorption[NCT04754724] | 31 participants (Actual) | Interventional | 2021-04-01 | Completed | |||
| A Randomized Open Label Trial Evaluating the Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)[NCT04501380] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-06-30 | Enrolling by invitation | ||
| Fructose and Lactose Intolerance and Malabsorption: the Relationship Between Metabolism and Symptoms in Functional Gastrointestinal Disorders[NCT02085889] | 3,000 participants (Anticipated) | Observational | 2019-03-01 | Recruiting | |||
| Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial[NCT02964195] | 308 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Comparison Between Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome Patients[NCT01803724] | 120 participants (Anticipated) | Observational | 2013-05-31 | Not yet recruiting | |||
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
6 reviews available for methane and Cholera Infantum
| Article | Year |
|---|---|
Hydrogen cross-feeders of the human gastrointestinal tract.
Topics: Acetates; Animals; Archaea; Bacteria; Gastrointestinal Diseases; Gastrointestinal Microbiome; Humans | 2019 |
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.
Topics: Adult; Bacterial Infections; Breath Tests; Cathartics; Child; Diet; Dietary Carbohydrates; Evidence- | 2009 |
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.
Topics: Adult; Bacterial Infections; Breath Tests; Cathartics; Child; Diet; Dietary Carbohydrates; Evidence- | 2009 |
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.
Topics: Adult; Bacterial Infections; Breath Tests; Cathartics; Child; Diet; Dietary Carbohydrates; Evidence- | 2009 |
Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference.
Topics: Adult; Bacterial Infections; Breath Tests; Cathartics; Child; Diet; Dietary Carbohydrates; Evidence- | 2009 |
Metabolic, phylogenetic, and ecological diversity of the methanogenic archaea.
Topics: Animals; Archaea; Biomass; Ecosystem; Gastrointestinal Diseases; Genetic Variation; Humans; Isoptera | 2008 |
Breath-analysis tests in gastroenterology.
Topics: Animals; Bile Acids and Salts; Blind Loop Syndrome; Breath Tests; Carbon Dioxide; Carbon Monoxide; C | 1974 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Application of Nanoparticles in the Diagnosis of Gastrointestinal Diseases: A Complete Future Perspective.
Topics: Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Inflammatory Bowel Diseases; Nanopart | 2023 |
2 trials available for methane and Cholera Infantum
| Article | Year |
|---|---|
Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacterial Infections; Breath Tests; Female; G | 2007 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
23 other studies available for methane and Cholera Infantum
| Article | Year |
|---|---|
[Single hydrogen-methane breath test for the diagnosis of small intestinal bacterial growth].
Topics: Bacteria; Breath Tests; Cross-Sectional Studies; Gastrointestinal Diseases; Humans; Hydrogen; Intest | 2023 |
THE IMPACT OF SMALL INTESTINAL BACTERIAL OVERGROWTH ON THE GROWTH OF CHILDREN AND ADOLESCENTS.
Topics: Bacterial Infections; Body Mass Index; Brazil; Breath Tests; Case-Control Studies; Child; Child Deve | 2020 |
Acute gastric injury after ingestion of substrate with hyperosmolar glucose and benzoate inversely related with small intestinal bacterial overgrowth.
Topics: Blind Loop Syndrome; Breath Tests; Endoscopy, Digestive System; Female; Gastrointestinal Diseases; G | 2020 |
Hydrogen-methane breath testing results influenced by oral hygiene.
Topics: Adolescent; Adult; Aged; Breath Tests; Dysbiosis; Exhalation; Female; Gases; Gastrointestinal Diseas | 2021 |
[Functional Exams in the gastroenterology - new developments and tips for the common practice].
Topics: Archaea; Breath Tests; COVID-19; Esophageal Achalasia; Esophagus; Gastrointestinal Diseases; Humans; | 2021 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus.
Topics: Blind Loop Syndrome; Breath Tests; Consensus; Fructose; Gastrointestinal Diseases; Glucose; Humans; | 2017 |
Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITOR.
Topics: Breath Tests; Gastrointestinal Diseases; Humans; Hydrogen; Methane; United States | 2017 |
Questioning the Utility of Breath Testing in Clinical Practice.
Topics: Breath Tests; Consensus; Gastrointestinal Diseases; Humans; Hydrogen; Methane; United States | 2017 |
Conflicts of Interest in the North American Consensus on Breath Testing.
Topics: Conflict of Interest; Consensus; Gastrointestinal Diseases; Humans; Hydrogen; Methane; United States | 2017 |
Response to Paterson et al.
Topics: Consensus; Gastrointestinal Diseases; Humans; Hydrogen; Methane; United States | 2017 |
Response to Maltz.
Topics: Consensus; Gastrointestinal Diseases; Humans; Hydrogen; Methane; United States | 2017 |
The North American Consensus on Breath Testing: The Controversial Diagnostic Role of Lactulose in SIBO.
Topics: Consensus; Gastrointestinal Diseases; Humans; Hydrogen; Lactulose; Methane; United States | 2018 |
Reply to Satta et al.
Topics: Breath Tests; Consensus; Gastrointestinal Diseases; Humans; Hydrogen; Methane; Racial Groups; United | 2018 |
Fermentable Sugar Ingestion, Gas Production, and Gastrointestinal and Central Nervous System Symptoms in Patients With Functional Disorders.
Topics: Abdominal Pain; Administration, Oral; Adult; Breath Tests; Central Nervous System Diseases; Cluster | 2018 |
Tricks for interpreting and making a good report on hydrogen and 13C breath tests.
Topics: Bacteria; Biomarkers; Breath Tests; Carbon Dioxide; Gases; Gastrointestinal Diseases; Gastrointestin | 2013 |
Association between small-intestinal bacterial overgrowth and deep vein thrombosis in patients with spinal cord injuries.
Topics: Adult; Bacterial Infections; Body Mass Index; Breath Tests; Female; Gastrointestinal Diseases; Gluco | 2017 |
Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection.
Topics: Adolescent; Breath Tests; Child; Child, Preschool; Cystic Fibrosis; Gastrointestinal Diseases; Human | 2009 |
Methane production during lactulose breath test is associated with gastrointestinal disease presentation.
Topics: Breath Tests; Colitis, Ulcerative; Constipation; Crohn Disease; Databases, Factual; Gastrointestinal | 2003 |
Factors affecting methane production in humans. Gastrointestinal diseases and alterations of colonic flora.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Colon; Colonoscopy; | 1987 |
[Bacteriological studies of the feces from methane-producers and nonproducers in the expired air].
Topics: Adult; Bacteriological Techniques; Euryarchaeota; Feces; Female; Gastrointestinal Diseases; Humans; | 1985 |
Methane excretion in man--a study of breath, flatus, and faeces.
Topics: Adolescent; Adult; Aged; Breath Tests; Colitis, Ulcerative; Colon; Crohn Disease; Feces; Female; Gas | 1985 |
Studies on the activity of a new antimycotic (Bay b 5097) in children.
Topics: Administration, Oral; Antifungal Agents; Benzene Derivatives; Candidiasis; Candidiasis, Cutaneous; C | 1972 |
[Value of a new antalgic-antispasmodic combination in gastroenterologic practice].
Topics: Adult; Aged; Analgesics; Drug Synergism; Female; Gastrointestinal Diseases; Humans; Male; Methane; M | 1969 |